EUVIMEDEUVIMED entdecken
Crossref

TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma

Marie Fredslund Breinholt iD, Lone Schejbel, Anne Ortved Gang, Ib Jarle Christensen, Torsten Holm Nielsen, Lars Møller Pedersen iD, Estrid Høgdall, Peter Nørgaard

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Marie Fredslund Breinholt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Herlev-Gentofte Hospital, Herlev, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Mutation, Tumor Suppressor Protein p53, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Large B‐cell lymphoma (LBCL) taxonomy has moved in the direction of a molecular classification, but further clinical experience is needed. We present high‐risk gene mutations, which predict outcome in an exploratory study of a consecutive real‐world cohort of patients with primary LBCL treated with R‐CHOP or R‐CHOP‐like therapy.

Methods

The study was a Registry Study Research Project. Sixty‐one patients with LBCL, who had a diagnostic tumor sample successfully examined with a 59‐gene next‐generation sequencing (NGS) panel as a part of routine clinical work, were included in an otherwise unselected cohort. Data were extracted from patient files and pathology reports.

Results

Mutations in NOTCH2 (HR 9.69; 95% CI [2.46–38.11]; p = 0.0012), PRDM1 (HR 3.54; 95% CI [1.03–12.22]; p = 0.045), and TP53 (HR 5.89; 95% CI [1.71–20.32]; p = 0.005) were significantly associated with inferior survival in patients with primary LBCL treated with intention to cure with at least three series of R‐CHOP or R‐CHOP‐like therapy. Neither MYD88 (HR 0.66; 95% CI (0.17–2.49), p = 0.54) nor CD79B (HR 0.84;95% CI (0.18–3.88), p = 0.82) mutations were associated with inferior survival.

Conclusion

With a targeted gene panel and NGS methodology feasible in daily diagnostic routine, we identified high‐risk gene mutations with a significant prognostic impact of which TP53 mutations were reproducible across validation cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseMutationTumor Suppressor Protein p53Biomarkers, TumorHumansMaleFemaleMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsAdultPrognosisHigh-Throughput Nucleotide SequencingTreatment OutcomeDoxorubicinCyclophosphamideAged, 80 and overRituximabVincristinePrednisone

Stichwörter der Autor:innen

NOTCH2PRDM1TP53hematologylarge B‐cell lymphomapathologyreal‐world data

Substanzen

Tumor Suppressor Protein p53Biomarkers, TumorDoxorubicinCyclophosphamideRituximabVincristinePrednisoneTP53 protein, humanR-CHOP protocol

Autor:innen und Institutionen

  • Department of Pathology, Herlev-Gentofte Hospital, Herlev, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Danish Medicines Agency, Copenhagen, Denmark.
  • Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Pathology, Hvidovre Hospital, Hvidovre, Denmark.

ORCID-Profile: Marie Fredslund Breinholt, Lars Møller Pedersen

Zitieren

APA

Breinholt, M. F., Schejbel, L., Gang, A. O., Christensen, I. J., Nielsen, T. H., Pedersen, L. M., Høgdall, E., & Nørgaard, P. (2025). TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.14364

Vancouver

Breinholt MF, Schejbel L, Gang AO, Christensen IJ, Nielsen TH, Pedersen LM, et al. TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma. European Journal of Haematology. 2025. doi:10.1111/ejh.14364

BibTeX
@article{Breinholt2025,
  author = {Breinholt, Marie Fredslund and Schejbel, Lone and Gang, Anne Ortved and Christensen, Ib Jarle and Nielsen, Torsten Holm and Pedersen, Lars Møller and Høgdall, Estrid and Nørgaard, Peter},
  title = {TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real‐Word Patients With Primary Large B‐Cell Lymphoma},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14364}
}
Kostenlos starten →